Effects of Acceptance and Commitment Care in the Treatment of Aplastic Anemia Patients with Recombinant Human Thrombopoietin.

Background: This study was designed to determine the effects of acceptance and commitment care in the treatment of aplastic anemia (AA) patients with recombinant human thrombopoietin (rhTPO).

Methods: The clinical records of 100 AA patients treated at our hospital from March 2021 to March 2023 were analyzed in the retrospective study. All patients received immunosuppressants and rhTPO. Among them, 46 patients who received routine care from March 2021 to March 2022 were allocated to the control group, and the other 54 patients who received acceptance and commitment care from April 2022 to March 2023 were assigned to the study group. The quality of life (QoL) of the 2 groups was assessed by the MOS 36-Item Short-Form Health Survey (SF-36) before care and after 3 months of care. Blood-related indicators after care were compared in 2 groups.

Results: Before care, no significant inter-group discrepancy was observed in SF-36 scores in all dimensions (P > .05); whereas after nursing, the SF-36 scores of both groups increased conspicuously in all dimensions (P < .001), especially the study group (P < .001). After care, no significant differences were observed in hemoglobin (Hb), platelet count (PLT), and white blood cell count (WBC) between the 2 groups (P > .05). A conspicuously lower overall response rate was observed in the control group in contrast to the study group (P = .044), and no significant inter-group discrepancy was found in the total incidence of adverse reactions (P = .506).

Conclusion: Acceptance and commitment care is conducive to the patients with AA treated by rhTPO, because it substantially improves the QoL of patients, without increasing adverse reactions, so it is worth promoting.